Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lutz, Philipp ^a,b   Parcina, Marijo ^a,b   Bekeredjian Ding, Isabelle ^a,b   Dieter Nischalke, Hans ^a,b   Nattermann, Jacob ^a,b   Sauerbruch, Tilman ^a   Hoerauf, Achim ^a,b   Strassburg, Christian P ^a,b   Spengler, Ulrich ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Center for Experimental and Clinical Infection Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PARACENTESIS; PASTEURELLA MULTOCIDA; PROSPECTIVE STUDY; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; SYSTEMIC THERAPY; BACTERIAL INFECTIONS; COMPLICATION; ENTEROCOCCUS; ISOLATION AND PURIFICATION; KLEBSIELLA; MICROBIOLOGY; MIDDLE AGED; PERITONITIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL INFECTIONS; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERITONITIS; PROSPECTIVE STUDIES; RIFAMYCINS; TREATMENT OUTCOME;

EID: 84899495323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093909     Document Type: Article

References (39)

1. Wiest R, Krag A, Gerbes A (2012) Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 61: 297-310.
2. Thuluvath PJ, Morss S, Thompson R (2001) Spontaneous bacterial peritonitis - in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 96: 1232-6 (Pubitemid 32319166)
3. Garcia-Tsao G (2001) Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120: 726-48.
4. Ginès P, Rimola A, Planas R, Vargas V, Marco F, et al. (1990) Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12: 716-24. (Pubitemid 20349256)
5. Coltart I, Tranah TH, Shawcross DL (2013) Inflammation and hepatic encephalopathy. Arch Biochem Biophys 536: 189-96
6. Häussinger D, Schliess F (2008) Pathogenetic mechanisms of hepatic encephalopathy. Gut 57: 1156-65.
7. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, et al. (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071-81.
8. Eltawil KM, Laryea M, Peltekian K, Molinari M (2012) Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 18: 767-77.
9. Scarpignato C, Pelosini I (2006) Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic. Digestion 73: Suppl 1:13-27.
10. Harputluoglu MM, Demirel U, Gul M, Temel I, Gursoy S, et al. (2012) Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. Inflammation 35: 1512-7.
11. Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, et al. (2012) Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 56: 893-9.
12. European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53: 397-417.
13. Blei AT, Córdoba J, Practice Parameters Committee of the American College of Gastroenterology (2001) Hepatic Encephalopathy. Am J Gastroenterol 96: 1968-76. (Pubitemid 32660887)
14. Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, et al. (2012) The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 46: 709-15
15. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, et al. (2012) Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55: 1551-61.
16. Tandon P, Delisle A, Topal JE, Garcia-Tsao G (2012) High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center. Clin Gastroenterol Hepatol 10: 1291-8.
17. Pelletier G, Salmon D, Ink O, Hannoun S, Attali P, et al. (1990) Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol 10: 327-31. (Pubitemid 20162740)
18. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, et al. (2013) Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 28: 450-5
19. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371: 838-851 (Pubitemid 351323895)
20. DuPont HL, Jiang ZD (2004) Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 10: 1009-11. (Pubitemid 39562470)
21. De Leo C, Eftimiadi C, Schito GC (1986) Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 12: 979-81 (Pubitemid 17040185)
22. Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, et al. (2013) Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of PAbN-inhibitable efflux pumps. Antimicrob Agents Chemother 57: 811-7.
23. Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, et al. (2011) Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect 62: 34-8.
24. Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutical potential in conditions mediated by gastrointestinal bacteria. Drugs 49: 467-484.
25. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, et al. (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 16: 111-8. (Pubitemid 23090031)
26. Tamaskar I, Ravakhah K (2004) Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J 97: 1113-5. (Pubitemid 39518707)
27. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R (2009) Severe sepsis in cirrhosis. Hepatology 50: 2022-33.
28. Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W (2009) Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 37: 2-8.
29. Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, et al. (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 8: e60042.
30. Rogers GB, van der Gast CJ, Bruce KD, Marsh P, Collins JE, et al. (2013) Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One 8:e74884
31. Bunchorntavakul C, Chavalitdhamrong D (2012) Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol 4: 158-68.
32. Tomás I, Diz P, Tobías A, Scully C, Donos N (2012) Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. Clin Periodontol 39: 213-28.
33. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, et al. (2010) The human oral microbiome. J Bacteriol 192: 5002-17.
34. Tanner A, Maiden MF, Paster BJ, Dewhirst FE (1994) The impact of 16S ribosomal RNA-based phylogeny on the taxonomy of oral bacteria. Periodontol 2000 5: 26-51.
35. Avril JL, Donnio PY, Pouedras P (1990) Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol 28: 1438-40.
36. Yakar T, Güçlü M, Serin E, Alişkan H, Husamettin E (2010) A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci 55: 1149-54.
37. Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, et al. (2010) Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 51: 1327-33
38. Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann M, et al. (2011) Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 55: 1010-6
39. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H (2000) In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 44: 2205-6 (Pubitemid 30484455)